Bladder Cancer Trial, Recruiting NCT07678489 Sponsor: Sami-Ramzi Leyh-Bannurah Condition: Bladder Cancer
Back to Bladder Cancer

Bladder Cancer Trial, Recruiting

NCT07678489
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People whose doctors estimate they have a life expectancy of 10 years or more based on their biological age
  • People who have not previously had any prostate treatments, such as laser surgery, TURP (a procedure to clear a blocked urethra), or focal therapy (targeted tumour treatment)
  • People who have not had radiation therapy to the pelvis or prostate
  • People who have not had previous surgery on the abdomen or rectum
  • People who have not had hormone therapy (androgen-deprivation therapy) to reduce testosterone before this point
  • People who have not had a stroke or reduced blood flow to the brain that left lasting neurological effects
  • People who do not have a neurological condition such as Parkinson's disease
  • People who have had a prostate biopsy taking at least 12 samples from both sides of the prostate, using MRI-guided and systematic methods
  • People whose PSA blood test result is 15 ng/mL or below, and whose prostate is 80 mL in size or smaller
  • People whose biopsy results show a cancer grade in the ISUP 1–3 range (also described as Gleason scores 3+3, 3+4, or 4+3)
  • People whose biopsy does not show certain more aggressive cancer patterns (specifically Gleason pattern 5, intraductal, cribriform, or neuroendocrine carcinoma)
  • People who have had a specific type of prostate MRI scan (required if the biopsy Gleason score is 3+4 or higher)
  • People whose staging investigations show no signs that the cancer has spread to other parts of the body

Who may not be able to join:

  • People who do not meet any one of the inclusion criteria listed above
  • People who decline the trial procedure and instead choose to proceed with the standard robotic-assisted surgery as recommended under European urology guidelines

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Sami-Ramzi Leyh-Bannurah
Registry
ClinicalTrials.gov
Start date
30 January 2024
Est. completion
31 December 2030

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Technical feasibility of ToP-RAP; Perioperative safety (Clavien-Dindo); Time to urinary continence recovery

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov